<DOC>
	<DOCNO>NCT02899130</DOCNO>
	<brief_summary>This trial study effect polyherbal capsule lower viral load patient chronic Hepatitis B infection record incidence Hepatitis B surface antigen elimination 12 month</brief_summary>
	<brief_title>Effect Polyherbal Formulation Chronic Inactive Carriers Hepatitis B Virus</brief_title>
	<detailed_description>A placebo control randomised trial . 3 herbs proven effect eliminate virus normalize liver function give . Equally matched placebo ( blind ) give randomly patient . All parameter hepatitis B infection compare randomized group</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Adults age 18 year age , inactive chronic hepatitis B ( HB ) immune tolerant phase , without dyslipidaemia follow 1 . HBsAg +ve &gt; 6 month antiHBs negative 2 . Alanine amino transferase â‰¤ 2 upper limit normal 3 . HBeAg positive negative irrespective viral DNA load 4 . Not currently antiviral therapy Chronic hepatitis B Any one follow 1 . Patients decompensated liver disease etiology ( characterize elevate bilirubin , raise International normalized ratio , history ascites , variceal hemorrhage , hepatic encephalopathy , Spontaneous bacterial peritonitis , hepatorenal syndrome Hepatocellular carcinoma ) 2 . Family history hepatocellular carcinoma 3 . Patients HIV Hepatitis C virus comorbidity 4 . Pregnant , attempt conceive , lactate woman 5 . Patients diabetes mellitus 6 . Recent history acute coronary syndrome ( &lt; 6months ) chronic coronary artery disease poor leave ventricular function ( physician / cardiology opinion ) 7 . Patients renal failure ( Creatinine clearance le 60 ml/min ) 8 . Active substance alcohol abuse concurrent use corticosteroid immunosuppressive agent . 9 . Presence extra hepatic manifestation 10 . Previously treat pegylated interferon within last 2 year 11 . Positive fibroscan ultrasound elastography show evidence fibrosis ( F3 ) 12 . Current former employee organic India 13 . Participating another clinical trial active intervention drug device last dose take within 60 day . 14 . Refusing consent physician uncomfortable patient compliance treatment follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>